Osmotic Demyelination Syndrome Resulting from an Unexpected Response to Tolvaptan in a Patient with Heart Failure / 대한내과학회지
Korean Journal of Medicine
;
: 62-65, 2017.
Article
in Korean
| WPRIM
| ID: wpr-194638
ABSTRACT
Hyponatremia is commonly encountered in patients with heart failure and has a poor prognosis. Tolvaptan, a novel selective vasopressin V2 receptor blocker, has received attention as an effective drug for treating the syndrome of inappropriate antidiuretic hormone secretion and hypervolemic hyponatremia. However, the safety of tolvaptan in the treatment of hyponatremia is not clear. We experienced a 78-year-old woman with a history of heart failure, atrial fibrillation, and hyponatremia who developed osmotic demyelination syndrome as an unexpected response to treatment with tolvaptan.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Prognosis
/
Atrial Fibrillation
/
Demyelinating Diseases
/
Receptors, Vasopressin
/
Heart
/
Heart Failure
/
Hyponatremia
Type of study:
Prognostic study
Limits:
Aged
/
Female
/
Humans
Language:
Korean
Journal:
Korean Journal of Medicine
Year:
2017
Type:
Article
Similar
MEDLINE
...
LILACS
LIS